Monogram provides FAQs on Zimmer Biomet acquisition: $4.04 cash + CVRs up to $3.43 per share

Monogram Technologies Inc.

Each share to receive $4.04 cash plus one CVR with potential payments from $1.04 to $3.43 per CVR contingent on milestones.
Merger expected to close in H2 2025, subject to regulatory and stockholder approval.
CVRs are non-tradeable, non-transferable, and provide no guaranteed payments.
Monogram shares will be delisted from Nasdaq upon closing.
Stockholders need not take immediate action; proxy statement to be mailed in 1-2 months.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.